Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Essex Property Trust, Inc. (ESS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Essex Property Trust, Inc.Trade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Essex Property Trust, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Essex Property Trust, Inc. trades at $282.1 (market cap $18.15B), while State Street SPDR S&P Biotech ETF trades at $158.81. The key difference: Essex Property Trust, Inc. pays a 3.93% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Essex Property Trust, Inc. nearer its low. Which is the better fit depends on your goals.

ESSXBI
Market Cap
$18.15B
Sector
Real EstateBroad Market / Factor
52-Week High
$298.33$164.28
52-Week Low
$239.61$86.92
Enterprise Value
$24.75B
Dividend Yield
3.93%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Essex Property Trust, Inc.

ESS trades at $281.92, down 0.46% on the day, with a bearish technical signal from moving averages and oscillators. The company reported a Q2 2026 EPS miss ($0.97 vs. $1.46 expected) but raised full-year guidance, reflecting strong property NOI growth. Revenue reached $1.89B in 2025 with a net income margin of 35.48%, though profitability is projected to moderate in 2026. Recent news highlights institutional buying by Amundi and recognition as a top GreenTech company.

The outlook is mixed: raised guidance and solid fundamentals support upside toward the $305.86 consensus price target, but technical weakness and a high debt load pose near-term risks. Investor sentiment is cautiously optimistic, with 40% of analysts rating the stock a Buy, though the bearish technical picture suggests potential volatility ahead.

State Street SPDR S&P Biotech ETF

XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.

Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.

Returns comparison

Trailing returns across standard periods

About Essex Property Trust, Inc.

Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.

Read more on ESS

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI